News

Earlier in February 2010, Meda has got exclusive license for marketing, selling and distributing Xerese in the US, Canada and Mexico for the treatment of cold sores (herpes

The approval is based on the satisfactory results obtained from a 9-week, multicenter, double-blind, randomized, placebo-controlled study of INTUNIV in combination with a stimulant in children and adolescents

Under the pact, Novavax will provide VLP technology transfer and manufacturing support for LGLS’s new vaccine production facility. As per the agreement, LGLS will be manufacture, develop and

Novavax has got $97m for first three years with an option to extend for additional two years for a total contract value of $179.1m. However, HHS has awarded

The company claims that Daliresp is a once-daily oral tablet and is the first and only selective PDE4 inhibitor approved by the FDA.Daliresp will be available across the

Gralise tablet is developed by Depomed and is licensed to Abbott Products in US, Mexico and Canada. The FDA has approved Gralise tablets as once daily treatment of

The preclinical programmes of AFFiRiS’ two vaccine candidates, generated by its AFFITOME technology, have been completed successfully. Meanwhile, its lead vaccine candidate AD02 is currently in phase II

Health Robotics claims that CytoCare guarantees a dosage accuracy within 95%+. The therapeutic window of medications can be optimally used, providing your patients with the most effective treatment.

Two classes of bowel cancer cells grown in the lab were treated with around 250 compounds including common chemotherapy drugs used in bowel cancer and newer ‘targeted’ drugs